For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Cagrilintide
Illustration for Cagrilintide

THE PEPSRADAR ENCYCLOPEDIA

Cagrilintide

Amylin signaling and appetite research

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Cagrilintide · KEY FACTS

Content updated · how dates work

Saved peptides

Compare: Eloralintide vs Cagrilintide

What is Cagrilintide?

Cagrilintide is an amylin analogue investigated for weight management. Its evidence must be separated from evidence for combinations containing it.

Video overview · 3:21

CagriSema (Cagrilintide + Semaglutide): Better Than Wegovy? What the Trials Show

How amylin works, the REDEFINE trials (including how much the cagrilintide half adds), the head-to-head with tirzepatide, side effects, CagriSema's FDA review, and why research vials are not the trial drug.

Narrated with an AI voice from this profile's sources; education only, no dosing.

Read the transcript

CagriSema is Novo Nordisk's next weight-loss drug: cagrilintide, an amylin drug, combined with semaglutide, the drug in Wegovy. In its biggest trial, people lost about twenty percent of their weight on average. It's under FDA review, but it's not approved. Here's what the trials show.

Amylin is a hormone your pancreas releases along with insulin after a meal. It signals fullness and slows how fast your stomach empties. Cagrilintide is a long-acting version, given as a weekly injection. CagriSema pairs it with semaglutide, so it works on two hormone signals at once.

Here's the idea. Cagrilintide acts on amylin receptors, semaglutide on GLP-1 receptors, and both push appetite down. In trials, the pair beat either drug alone. Whether it beats the strongest drug already on the market is a different question.

Cagrilintide alone came first: in a 2021 trial of 706 adults, weight loss ranged from about six to eleven percent over 26 weeks, versus three percent on placebo. Then the big one, REDEFINE 1: 3,417 adults over 68 weeks. Average weight loss was about twenty percent on CagriSema, fifteen on semaglutide alone, eleven and a half on cagrilintide alone, and three on placebo.

The comparisons are mixed. Before REDEFINE 1, Novo had signaled about twenty-five percent, and its shares fell about a fifth when the results came in lower. In type 2 diabetes, CagriSema beat semaglutide alone, about thirteen versus nine percent. But head to head with tirzepatide, the drug in Zepbound, it fell short: about twenty versus twenty-four percent.

Side effects were common. In REDEFINE 1, stomach and gut side effects hit about eighty percent of people on CagriSema, versus forty on placebo, mostly nausea, constipation and vomiting. About six percent stopped because of side effects. These trials were funded by Novo Nordisk.

Novo filed CagriSema with the FDA in December 2025 and expects a decision by late 2026. It is not approved in the US or Europe. A heart-outcomes trial of about seven thousand people is still running. And the FDA says cagrilintide can't be used in compounding, and has warned sellers of research-use cagrilintide that their products are unapproved drugs.

Does CagriSema beat Wegovy? Supported: about twenty versus fifteen percent in REDEFINE 1. Does it beat Zepbound? Not supported: it fell short head to head. Does cagrilintide work alone? Limited: smaller effects, in fewer trials. And are research vials the trial drug? No: the FDA calls them unapproved drugs.

The bottom line: adding cagrilintide to semaglutide adds real weight loss, about twenty percent in the biggest trial. But it fell short of tirzepatide head to head, side effects are common, and it's still under FDA review. For every study and source, see the cagrilintide profile on PepsRadar dot com.

Biological role or research focus

Amylin signaling and appetite research.

Cagrilintide alone and CagriSema, the combination with semaglutide, are different study treatments.

Role reference: Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. ↗

Names you may encounter

CagriSema

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Long-acting amylin analogue
Main research area
Satiety and weight management research
Evidence featured
Human phase 2 randomized trial
Source check
October 4, 2026

Source: Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. ↗

Quick answers

Is Cagrilintide FDA approved?
No. No FDA-approved drug contains Cagrilintide. Source ↗
Is Cagrilintide safe?
Cagrilintide is an investigational amylin analogue. In trials, digestive side effects and injection-site reactions were common; long-term safety and rare harms are not yet known. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
Is Cagrilintide banned in sport?
Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
Has the FDA taken action over Cagrilintide?
Yes. Our records list 3 FDA actions naming it, most recently on October 1, 2026: FDA states that cagrilintide cannot be used in compounding under federal law and is not a component of any FDA-approved drug (page updated October 1, 2026). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

3 Human research
StudyTypePopulation / model
Cagrilintide dose-finding study (2021)Human phase 2 randomized trial706 adults with obesity, or overweight with hypertension or dyslipidemia, without diabetes.
REDEFINE 1 · CagriSema (2025)Human phase 3 randomized trial3,417 adults with obesity, or overweight with an obesity-related complication, without diabetes.
REDEFINE 2 · CagriSema in diabetes (2025)Human phase 3 randomized trial1,206 adults with type 2 diabetes and BMI of at least 27.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human phase 2 randomized trial · 2021

Cagrilintide dose-finding study

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

Population / model
706 adults with obesity, or overweight with hypertension or dyslipidemia, without diabetes.
Study design
26 weeks; placebo and liraglutide comparators; participants were not blinded between different active treatments.
Main finding
Estimated mean weight reduction ranged from 6.0% to 10.8% across cagrilintide groups versus 3.0% with placebo in the trial-product analysis. Gastrointestinal and injection-site events were frequent.
Limits & context
This is monotherapy evidence. It cannot be presented as the result for CagriSema or for an unidentified seller blend; longer-term outcomes require separate studies.

Source: Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. ↗

Human phase 3 randomized trial · 2025

REDEFINE 1 · CagriSema

What did the combination achieve in adults without diabetes?

Population / model
3,417 adults with obesity, or overweight with an obesity-related complication, without diabetes.
Study design
68-week blinded trial of the combination, each component separately, or placebo; all groups received lifestyle intervention.
Main finding
Estimated weight change was −20.4% with the combination versus −3.0% with placebo under the treatment-policy analysis. Gastrointestinal events occurred in 79.6% versus 39.9%.
How to read it
These headline results concern cagrilintide plus semaglutide, not cagrilintide alone.
Limits & context
The analysis includes treatment discontinuation. Different estimands can produce different headlines. It does not establish long-term cardiovascular benefit or equivalence to a seller blend. Funded by Novo Nordisk.

Source: REDEFINE 1 · CagriSema · 2025 ↗

Human phase 3 randomized trial · 2025

REDEFINE 2 · CagriSema in diabetes

How did the combination perform in a separate diabetes population?

Population / model
1,206 adults with type 2 diabetes and BMI of at least 27.
Study design
68-week blinded comparison of the combination with placebo, alongside lifestyle intervention; treatment-policy analysis.
Main finding
Estimated weight change was −13.7% versus −3.4%. HbA1c of 6.5% or lower was reached by 73.5% versus 15.9%. Gastrointestinal events occurred in 72.5% versus 34.4%.
How to read it
This population and comparator differ from REDEFINE 1; the percentages are not a direct head-to-head comparison.
Limits & context
Without separate component arms, this trial cannot isolate cagrilintide’s contribution. Weight and glucose endpoints do not prove longer survival or validate research-use mixtures. Funded by Novo Nordisk.

Source: REDEFINE 2 · CagriSema in diabetes · 2025 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

45 registered studies name Cagrilintide as an intervention; 18 are recruiting or under way, 1 has not started recruiting yet, 24 completed and 2 ended early, were withdrawn or have another status. Checked November 14, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
NCT07919405 · Novo Nordisk A/S
Not yet recruitingPhase 32026-11-111408
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06221969 · Novo Nordisk A/S
CompletedPhase 32024-01-161024
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT07607587 · Novo Nordisk A/S
RecruitingPhase 12026-05-29114
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
NCT07282613 · Novo Nordisk A/S
RecruitingPhase 32026-08-0480
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
NCT06534411 · Novo Nordisk A/S
CompletedPhase 32024-11-051023
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759 · Novo Nordisk A/S
Active, not recruitingPhase 32025-11-05330
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
NCT07817251 · Novo Nordisk A/S
RecruitingPhase 32026-09-16210
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
NCT06323174 · Novo Nordisk A/S
CompletedPhase 32024-03-19189

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 45 listed studies.

Search additional PubMed records ↗

Risks & interactions

Cagrilintide is an investigational amylin analogue. In trials, digestive side effects and injection-site reactions were common; long-term safety and rare harms are not yet known.

Human safety data: Trials only

A phase 2 trial of cagrilintide alone and phase 3 trials of the cagrilintide-semaglutide combination report safety data. Combination results do not isolate cagrilintide, and trial lengths cannot rule out rare or long-term harms.

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Side effects reported in studies

  • nausea
  • constipation
  • diarrhea
  • vomiting
  • abdominal pain
  • injection-site reactions

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Cagrilintide phase 2 dose-finding trial (Lancet, 2021) ↗ · REDEFINE 1: cagrilintide with semaglutide (NEJM, 2025) ↗ · REDEFINE 2: cagrilintide with semaglutide in type 2 diabetes (NEJM, 2025) ↗ · FDA: Concerns with unapproved GLP-1 drugs used for weight loss ↗

Safety evidence & remaining uncertainty

Gastrointestinal symptoms and injection-site reactions occurred in the phase 2 trial. A relatively short study cannot resolve uncommon harms or tolerability over many years.

Source: Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source

FDA actions

  • FDA states that cagrilintide cannot be used in compounding under federal law and is not a component of any FDA-approved drug (page updated October 1, 2026). (2026-10-01) source
  • FDA warning letter to a "research peptide" seller (Prime Sciences) naming cagrilintide, mazdutide and GLP-1 products as unapproved new drugs. (2026-03-31) source
  • FDA warning letter to a "research peptide" seller (Xcel Research) naming cagrilintide, "CagriLean" (cagrilintide plus semaglutide), retatrutide and others as unapproved new drugs despite research-use-only labeling. (2024-12-10) source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & status

The selected study evaluates cagrilintide alone. CagriSema combines cagrilintide with semaglutide and has a separate clinical development program. This page does not present a trial record as a product approval.

Source: Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. This drug is still investigational and is not approved for sale. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).

Mechanism & research rationale

Amylin is a pancreatic satiety signal. Cagrilintide was designed to provide longer-lasting activity, and clinical development tests whether that signaling translates into sustained weight reduction.

Source: Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. ↗

Molecular structure

Cagrilintide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 171397054 ↗

Questions worth asking

  • Is this cagrilintide alone or the CagriSema combination?
  • Are results available, or is the claim based only on a trial plan?
  • Cagrilintide alone and CagriSema, the combination with semaglutide, are different study treatments.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Is CagriSema simply another name for cagrilintide?

No. It is a combination with semaglutide; its efficacy and safety require separate evidence.

Source: Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. ↗

Can the best group average predict an individual result?

No. A group average depends on the study population, adherence, duration, and analysis; individuals vary.

Source: Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

PUT THE EVIDENCE IN CONTEXT

Research guides

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Cagrilintide

Download illustration ↓Source record ↗
Cagrilintide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.